Personalized approach to lipid-lowering therapy;Approche personnalisée du traitement des dyslipidémies

Revue Medicale de Liege

Volumn 70, Issue 5-6, 2015, Pages 292-298

  Scheen, A J ^a   Descamps, O S ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Hospital de Jolimont   (Belgium)

Author keywords

Cardiovascular risk; Cholesterol; Familial hypercholesterolemia; Genetics; PCSK9 protein

Indexed keywords

FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; ANTILIPEMIC AGENT; LIPID; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIPID ANALYSIS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; BLOOD; DYSLIPIDEMIAS; GENETICS; INDIVIDUALITY; PHYSIOLOGY; PROCEDURES;

DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INDIVIDUALITY; INDIVIDUALIZED MEDICINE; LIPIDS; PHENOTYPE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84931836397     PISSN: 0370629X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Reiner Z, Catapano AL, De Backer G, et al., ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011, 32, 1769-1818.
2. Chapman MJ, Ginsberg HN, Amarenco P, et al., Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur Heart J, 2011, 32, 1345-1361.
3. Descamps OS, De Backer G, Annemans L, et al., Les nouvelles recommandations européennes pour le traitement des dyslipidémies en prévention cardiovasculaire. Rev Med Liège, 2012, 67, 118-127.
4. Descamps OS, Scheen AJ, De Backer G, et al., Comment je traite ⋯ une dyslipidémie en fonction du profil de risque cardiovasculaire. Rev Med Liège, 2012, 67, 167-173.
5. Fredrickson DS, Lees RS., A system for phenotyping hyperlipoproteinemia. Circulation, 1965, 31, 321-327.
6. Fredrickson DS -Phenotyping. On reaching base camp (1950-1975). Circulation, 1993, 87, III1-15.
7. Scheen AJ., Le traitement des hyperlipidémies. Rev Med Liège, 1992, 47, 169-184.
8. Scheen AJ, Radermecker R, De Flines J, et al., Actualités thérapeutiques en lipidologie. Rev Med Liège, 2007, 62, 324-328.
9. Scheen AJ, Kulbertus H., Prévention cardio-vasculaire par les statines: Faut-il encore doser le cholestérol? Rev Med Liège, 2003, 58, 191-197.
10. Baigent C, Blackwell L, Emberson J, et al., Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010, 376, 1670-1681.
11. Descamps OS, De Backer G, Scheen AJ, et al., Étude " IMPROVE-IT " : Bénéfice de l'ajout d'ézétimibe à une statine pour prévenir les maladies cardiovasculaires, commentaire de la Société Belge d'Athérosclérose/Belgian Lipid Club. Louvain Med, 2014, 133, 692-701.
12. Ducobu J, Scheen AJ, Legat P, et al., Place des fibrates dans le traitement de patients avec une dyslipidémie athérogène. Rev Med Liège, 2009, 64, 512-518.
13. Ginsberg HN, Elam MB, Lovato LC, et al., Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010, 362, 1563-1574.
14. Scheen AJ, Van Gaal LF., ACCORD-LIPID et ACCORD-EYE : Vers un nouveau positionnement du fénofibrate chez le patient diabétique de type 2. Rev Med Liège, 2010, 65, 533-539.
15. Group HTC, Landray MJ, Haynes R, et al. -Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med, 2014, 371, 203-212.
16. Scheen AJ. -Comment j'explore ⋯ le risque cardio-vasculaire absolu à 10 ans: De Framingham 1998 à SCORE 2003. Rev Med Liège, 2004, 59, 460-466.
17. Descamps OS, Cooney MT, De Backer G, et al., A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. Atherosclerosis, 2012, 222, 564-566.
18. Descamps OS., Tableau SCORE adapté pour le HDL-cholestérol, une mise à jour. Louvain Med, 2013, 132, 1-4.
19. Stone NJ, Robinson JG, Lichtenstein AH, et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129, S1-45.
20. Descamps OS, Rietzschel ER, Langlois M, et al., Qu'apportent les nouvelles recommandations américaines sur la prise en charge des dyslipidémies en prévention cardiovasculaire ? Comparaison avec les recommandations européennes et belges. Louvain Med, 2014, 133, 26-35.
21. Davignon J, Genest J Jr., Genetics of lipoprotein disorders. Endocrinol Metab Clin North Am, 1998, 27, 521-550.
22. Descamps OS., Familial hypercholesterolaemia in a Belgian community. Acta Cardiol, 2000, 55, 327-333.
23. Descamps OS., Hypercholestérolémie familiale. J Cardiol, 2015, 27, 145-150.
24. Cuchel M, Bruckert E, Ginsberg HN, et al., Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J, 2014, 35, 2146-2157.
25. Descamps OS, Tenoutasse S, Stephenne X, et al., Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis, 2011, 218, 272-280.
26. Nordestgaard BG, Chapman MJ, Humphries SE, et al., Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013, 34, 3478-3490a.
27. Raal FJ, Honarpour N, Blom DJ, et al., Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B) : A randomised, double-blind, placebo-controlled trial. Lancet, 2015, 385, 341-350.
28. Raal FJ, Stein EA, Dufour R, et al., PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet, 2015, 385, 331-340.
29. Talmud PJ, Shah S, Whittall R, et al., Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. Lancet, 2013, 381, 1293-1301.
30. Hegele RA, Ginsberg HN, Chapman MJ, et al., The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol, 2014, 2, 655-666.
31. Rosenson RS, Davidson MH, Hirsh BJ, et al., Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol, 2014, 64, 2525-2540.
32. Radermecker RP, Scheen AJ., Distinction entre patients bons synthétiseurs et bons absorbeurs pour optimiser le traitement hypocholesterolémiant. Rev Med Suisse, 2006, 2, 1910-1915.
33. Descamps OS, De Sutter J, Guillaume M, et al., Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today? Atherosclerosis, 2011, 217, 308-321.
34. Descamps O, Tomassini JE, Lin J, et al., Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis, 2015, 240, 482-489.
35. Bousoula E, Kolovou V, Perrea D, et al., Pharmacogenetics and statin treatment: Reality or theory? Curr Vasc Pharmacol, 2015, Jan 30. [Epub ahead of print].
36. Hu M, Tomlinson B., Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics, 2013, 14, 981-995.
37. Postmus I, Trompet S, Deshmukh HA, et al., Pharmacogenetic meta-Analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Commun, 2014, 5, 5068.
38. Maggo SD, Kennedy MA, Clark DW., Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf, 2011, 34, 1-19.
39. Giorgi MA, Caroli C, Arazi HC, et al., Pharmacogenomics and adverse drug reactions: The case of statins. Expert Opin Pharmacother, 2011, 12, 1499-1509.
40. Mega JL, Stitziel NO, Smith JG, et al., Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: An analysis of primary and secondary prevention trials. Lancet, 2015, Mar 3. pii: S0140-6736(14)61730-X. doi: 10.1016/S0140-6736(14)61730-X. [Epub ahead of print].
41. Descamps OS, De Backer G, Balligand JL, et al., Les inhibiteurs de PCSK9 : Une nouvelle stratégie pour abaisser le LDL-cholestérol et prévenir les maladies cardiovasculaires. Louvain Med, 2014, 133, 566-576.
42. Cohen JC, Boerwinkle E, Mosley TH, Jr., et al., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med, 2006, 354, 1264-1272.
43. Navarese EP, Kolodziejczak M, Schulze V, et al., Effects of Proprotein Convertase Subtilisin/Kexin Type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-Analysis. Ann Intern Med, 2015, Apr 28. doi: 10.7326/M14-2957. [Epub ahead of print].
44. Wu NQ, Li S, Li JJ., Update of clinical trials of anti-PCSK9 antibodies. Cardiovasc Drugs Ther, 2015, 29, 159-169.